Zhejiang Jingxin Pharmaceutical Co., LTD
Zhejiang Jingxin Pharmaceutical (est. 1990) is a listed national high-tech enterprise specializing in psycho-neural/cardiovascular drugs. With 8.48B CNY assets and 3,900+ employees (230+ PhDs/master's), it operates dual HQs in Xinchang/Hangzhou, 6 production bases, a Yunnan breeding site, and a Shanghai R&D institute. Globally partnered with ventures/labs in US, Denmark, Israel, etc., it passed German GMP (2006) and FDA audits (2018), maintaining China's Pharma Top 100 status. Equipped with national tech center/post-doctoral station, it collaborates with CAS, Zhejiang University, etc. Achievements include 8 national key new drugs, 9 Torch Program projects, and 222 patents (156 domestic, 2 US) by 2024.